Capital Impact Advisors’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-12,572
Closed -$531K 17
2024
Q2
$531K Sell
12,572
-8,707
-41% -$479K 1.49% 40
2024
Q1
$1.47M Buy
21,279
+12,585
+145% +$796K 1.91% 13
2023
Q4
$643K Buy
8,694
+4,584
+112% +$300K 0.85% 60
2023
Q3
$280K Hold
4,110
0.47% 86
2023
Q2
$386K Sell
4,110
-757
-16% -$59.1K 0.42% 113
2023
Q1
$330K Sell
4,867
-1,609
-25% -$103K 0.4% 116
2022
Q4
$321K Buy
6,476
+1,043
+19% +$42.6K 0.31% 140
2022
Q3
$201K Buy
5,433
+2,612
+93% +$108K 0.2% 180
2022
Q2
$111K Sell
2,821
-4,052
-59% -$217K 0.1% 217
2022
Q1
$481K Buy
+6,873
New +$502K 0.35% 136
2021
Q4
Sell
-13,400
Closed -$1.28M 112
2021
Q3
$1.28M Sell
13,400
-33,988
-72% -$3.59M 0.51% 84
2021
Q2
$5.4M Buy
47,388
+37,854
+397% +$4.52M 1.74% 7
2021
Q1
$1.26M Sell
9,534
-60,168
-86% -$8.24M 0.44% 81
2020
Q4
$9.23M Buy
69,702
+5,000
+8% +$605K 2.27% 4
2020
Q3
$6.6M Buy
+64,702
New +$5.59M 1.95% 8

Other funds holding EXAS

Capital Impact Advisors's EXAS Position: Q3 2024 in Review

Capital Impact Advisors sold out of Exact Sciences (EXAS) in Q3 2024, closing a stake of 12,572 shares — an estimated $531K sold.

Capital Impact Advisors first reported a position in EXAS in Q3 2020 and held it in 15 quarters. The position peaked at $9.23M in Q4 2020. 598 funds tracked by Wall St. Rank hold EXAS as of Q3 2024.

  • Capital Impact Advisors reported no remaining Exact Sciences position as of Q3 2024 after selling out during the quarter.
  • Capital Impact Advisors sold 12,572 Exact Sciences shares in Q3 2024, an estimated $531K.
  • Capital Impact Advisors first reported a position in Exact Sciences in Q3 2020 and held it in 15 quarters.
  • Capital Impact Advisors's Exact Sciences position peaked at $9.23M in Q4 2020.
  • 598 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2024.

Based on Capital Impact Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.